Skip to main
ADPT
ADPT logo

Adaptive Biotechnologies (ADPT) Stock Forecast & Price Target

Adaptive Biotechnologies (ADPT) Analyst Ratings

Based on 9 analyst ratings
Buy
Strong Buy 56%
Buy 33%
Hold 11%
Sell 0%
Strong Sell 0%

Bulls say

Adaptive Biotechnologies Corp is expected to experience a substantial growth in gross profit, driven by increases in average selling price (ASP) and improvements in sequencing margins associated with the transition to the NovaSeq X technology. The company's financial position related to minimal residual disease (MRD) diagnostics is forecasted to enhance further in 2025, supported by incremental volume growth and ASP improvements contributing to revenue uplift. Additionally, the 17% increase in episode pricing is anticipated to catalyze ASPs nearing the longer-term target of exceeding $1,300, positioning the company for continued financial advancement.

Bears say

The financial outlook for Adaptive Biotechnologies Corp suggests a stagnation in Immune Medicine revenue, with expectations of flat growth due to ongoing efforts to generate interest in their TCR-Antigen model and develop their autoimmunity program. Additionally, a significant challenge is highlighted by the fact that approximately 25% of patients receiving an ID test do not go on to receive an MRD test within a year, negatively impacting the average test frequency and potential revenue. Despite holding a leadership position in the market, these factors contribute to an overall negative financial forecast for the company.

Adaptive Biotechnologies (ADPT) has been analyzed by 9 analysts, with a consensus rating of Buy. 56% of analysts recommend a Strong Buy, 33% recommend Buy, 11% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Adaptive Biotechnologies and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Adaptive Biotechnologies (ADPT) Forecast

Analysts have given Adaptive Biotechnologies (ADPT) a Buy based on their latest research and market trends.

According to 9 analysts, Adaptive Biotechnologies (ADPT) has a Buy consensus rating as of Dec 5, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $16.56, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $16.56, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Adaptive Biotechnologies (ADPT)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.